Imatinib Mesylate: Brands, Price & Uses in Bangladesh

Imatinib Mesylate is an oral tyrosine kinase inhibitor used, under the supervision of an oncologist/hematologist, in the following disease states classified by strength of evidence:

FDA-Approved / Established Indications

• Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, in adult and pediatric patients.
• Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, in adults and children.
• Relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults, generally used as a single agent.
• Newly diagnosed Ph+ ALL in adult and pediatric patients, in combination with chemotherapy.
• Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements, in adults.
• Aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation, or with unknown c-Kit mutation status, in adults.
• Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα fusion kinase (or FIP1L1-PDGFRα-negative/unknown), in adults.
• Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP), in adults.
• Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST), in adults.
• Adjuvant treatment after surgical resection of Kit-positive GIST, in adults.

Because of the seriousness of these conditions and the need for individualized dosing and close monitoring, Imatinib Mesylate should only be initiated and supervised by a physician experienced in the management of hematologic malignancies or sarcomas.

Adult Dosing by Indication

Pediatric Dosing

Dose Adjustment in Hepatic Impairment

Mild to moderate hepatic impairment: standard starting dose is generally used with close monitoring. Severe hepatic impairment: the recommended dose should be reduced by approximately 25%, with careful monitoring of liver function and tolerability.

Dose Adjustment in Renal Impairment

Mild renal impairment (CrCl 40-59 mL/min): maximum recommended dose 600 mg/day. Moderate renal impairment (CrCl 20-39 mL/min): starting dose reduced by about 50%, with cautious up-titration if tolerated. Severe renal impairment: use with caution at lower doses under close specialist supervision.

Administration

Imatinib Mesylate should be taken exactly as prescribed by the treating oncologist/hematologist - do not stop, change the dose, skip doses, or share this medicine with others without medical advice, as under-dosing or interruption can lead to loss of disease control and drug resistance.

Adverse effects of Imatinib Mesylate are generally dose-related and manageable with monitoring; some are common, and others are serious and require prompt medical attention.

Very Common (≥30%)

• Fluid retention/edema (periorbital or peripheral)
• Nausea and vomiting
• Muscle cramps and musculoskeletal pain
• Diarrhea
• Skin rash
• Fatigue
• Abdominal pain
• Headache

Common

• Mild to moderate liver enzyme elevations
• Cytopenias (mild anemia, neutropenia, thrombocytopenia)
• Dyspepsia, weight changes
• Dizziness, insomnia

Serious/Less Common - Require Medical Attention

• Severe fluid retention: pleural effusion, pericardial effusion, ascites, pulmonary edema, rapid weight gain (see Precautions and Warnings)
• Severe hepatotoxicity, including rare fatal liver failure (see Precautions and Warnings)
• Severe myelosuppression: Grade 3/4 neutropenia and thrombocytopenia requiring blood count monitoring
• Gastrointestinal or other hemorrhage, including from GIST tumor sites
• Cardiac dysfunction, including congestive heart failure and reduced left ventricular function (rare but serious)
• Gastrointestinal perforation (rare)
• Severe skin reactions (e.g., Stevens-Johnson syndrome - rare)
• Tumor lysis syndrome, particularly with high tumor burden at treatment initiation

Patients should seek prompt medical attention for sudden weight gain, shortness of breath, swelling, unusual bleeding or bruising, yellowing of skin/eyes, severe abdominal pain, or signs of infection.